vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.
Company profile
Ticker
VYNE
Exchange
Website
CEO
David Domzalski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
VYNE Pharmaceuticals Ltd. • VYNE Pharmaceuticals Inc. ...
VYNE stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Mar 24
S-3
Shelf registration
1 Mar 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
29 Feb 24
8-K
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
3 Jan 24
S-8
Registration of securities for employees
13 Dec 23
8-K
Departure of Directors or Certain Officers
13 Dec 23
EFFECT
Notice of effectiveness
24 Nov 23
424B3
Prospectus supplement
22 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.50 mm | 15.50 mm | 15.50 mm | 15.50 mm | 15.50 mm | 15.50 mm |
Cash burn (monthly) | 1.73 mm | 1.67 mm | 2.08 mm | 2.53 mm | 1.72 mm | 2.08 mm |
Cash used (since last report) | 11.91 mm | 11.50 mm | 14.28 mm | 17.42 mm | 11.80 mm | 14.33 mm |
Cash remaining | 3.59 mm | 4.00 mm | 1.22 mm | -1.91 mm | 3.70 mm | 1.18 mm |
Runway (months of cash) | 2.1 | 2.4 | 0.6 | -0.8 | 2.2 | 0.6 |
Institutional ownership, Q2 2023
2.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 7 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.38 bn |
Total shares | 374.93 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
DSC Advisors | 115.00 k | $466.90 mm |
Susquehanna International | 76.38 k | $310.10 mm |
BLK Blackrock | 49.11 k | $201.35 mm |
Vanguard | 44.90 k | $184.07 mm |
Renaissance Technologies | 36.08 k | $148.00 k |
Geode Capital Management | 24.95 k | $101.28 mm |
STT State Street | 11.67 k | $47.36 mm |
Tekla Capital Management | 7.52 k | $30.53 mm |
BAC Bank Of America | 4.20 k | $17.22 mm |
MS Morgan Stanley | 2.21 k | $9.06 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | David Domzalski | Common Stock | Payment of exercise | Dispose F | No | No | 3.08 | 1,004 | 3.09 k | 494,160 |
1 Apr 24 | Mutya Harsch | Common Stock | Payment of exercise | Dispose F | No | No | 3.08 | 161 | 495.88 | 149,274 |
1 Apr 24 | Stuart Iain | Common Stock | Payment of exercise | Dispose F | No | No | 3.08 | 157 | 483.56 | 133,741 |
1 Apr 24 | Tyler Zeronda | Common Stock | Payment of exercise | Dispose F | No | No | 3.08 | 94 | 289.52 | 131,743 |
1 Jan 24 | Christine Borowski | Stock Option Common Stock | Grant | Acquire A | No | No | 2.33 | 40,000 | 93.20 k | 40,000 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
29 Feb 24
Recap: VYNE Therapeutics Q4 Earnings
29 Feb 24
VYNE Therapeutics Q4 Adjusted EPS $(0.18) Beats $(0.50) Estimate, Sales $76.00K Miss $150.00K Estimate
29 Feb 24
VYNE Therapeutics To Present Results Of Phase 1b Trial For VYN201 At 2024 Global Vitiligo Foundation Annual Scientific Symposium
27 Feb 24